N. Morsli

发表

LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.

G. Scagliotti, T. Nakano, J. V. van Meerbeeck, 2017, Clinical lung cancer.

Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

P. Sharma, L. Dirix, B. Keam, 2019, Clinical Cancer Research.

An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy

K. Goto, H. Kenmotsu, A. Sarashina, 2018, Cancer Chemotherapy and Pharmacology.

P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.

G. Scagliotti, R. Gaafar, N. Vogelzang, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.

J. Machiels, T. Seiwert, A. Psyrri, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Ferris, T. Ciuleanu, B. Keam, 2019, Journal of Clinical Oncology.

Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study

Damijan Miklavčič, C. Collins, Gerald C. O'Sullivan, 2006 .

Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma

L. Roskos, I. González-García, Xiang Guo, 2021, Oncoimmunology.

Response to 'Dai W et al. Am J Cancer Res 2015;5(10):3270-3275' from the makers of nintedanib.

J. Barrueco, N. Morsli, Claudia-Nanette Gann, 2016, American journal of cancer research.

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.

R. Ferris, T. Ciuleanu, B. Keam, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

M. Socinski, G. Scagliotti, S. Novello, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

S. Culine, J. Carles, J. Bellmunt, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.

R. Ferris, L. Licitra, R. Haddad, 2020 .

Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy

Helen Moore, I. González-García, S. Spencer, 2021, CPT: pharmacometrics & systems pharmacology.

Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study.

M. Nishio, N. Yamamoto, T. Tamura, 2011, Japanese journal of clinical oncology.

Electrochemotherapy: a new treatment of solid tumors.

L. Mir, C. Robert, M. Marty, 2003, Journal of experimental & clinical cancer research : CR.

Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU)

J. Carles, C. Théodore, L. Sengeløv, 2008 .

Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.

A. Matakidou, L. Siu, Z. Ghazoui, 2020 .

Phase I Study of Afatinib (BIBW 2992), An Erbb Family Blocker Plus Nintedanib (BIBF 1120), A Triple Angiokinase Inhibitor, in Patients (PTS) With Advanced Solid Tumours

J. Soria, H. Staines, A. Hollebecque, 2012 .

Industry corner: perspectives and controversies - The challenges of patient access to new medicines.

R. Kaiser, N. Morsli, Claudia-Nanette Gann, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

L. Siu, L. Licitra, R. Haddad, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Successful repetitive treatments by electrochemotherapy of multiple unresectable Kaposi sarcoma nodules

L. Mir, C. Robert, J. Garbay, 2006 .

Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial

M. Socinski, G. Scagliotti, N. Pavlakis, 2017 .

SPS-7Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial

G. Scagliotti, S. Novello, F. Grosso, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

L-BLP25 for unresectable stage III non-small cell lung cancer after primary chemoradiotherapy in Japanese patients: Preliminary safety results from a phase I/II study.

M. Nishio, N. Yamamoto, T. Tamura, 2010 .